Drug Development and Delivery: GigaGen CEO Dave Johnson discusses Why Understanding Immune Dysregulation is the Key to Drug Development

,

Antibodies have been used since the late 1980s as therapies to treat serious diseases, and demand is soaring to new heights today. However, conventional antibody drug discovery technologies are labor-intensive and slow. Pharmaceutical companies select drug candidates from just a small fraction of the antibodies that exist in a natural immune repertoire and have limited information on which candidates are the most promising. Additionally, identification and selection of drug targets remain an arduous process because conventional approaches to studying the immune system are not comprehensive. GigaGen Inc., based in South San Francisco, CA, has developed a unique insight into immune dysregulation through a proprietary technology known as Surge – a platform that quickly characterizes every cell in complex immune systems so that natural immune repertoires can be translated into medical treatments. The technology powers selection of drug targets, identification of drug candidates, and preclinical assessment of efficacy. GigaGen is using their insight into how the immune system functions to discover and develop drugs that solve disorders of immune dysregulation, including cancer and immune deficiency.

Read the full story.

GigaGen Announces Appointment of Sheila M. Keating, Ph.D., as Director, Immunology

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Sheila M. Keating, Ph.D., has joined the company as Director, Immunology. Dr. Keating will lead clinical development of GigaGen’s recombinant hyperimmune gammaglobulin product in collaboration with pharmaceutical partner Grifols. 

Read the full press release.

 

GigaGen CEO David Johnson to Present on the Power of Surge Technology to Discover Unique Immuno-oncology Antibodies at 14th Annual PEGS Summit

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the discovery of unique and functional antibodies utilizing Surge technology at the 14th Annual PEGS Summit. Dr. Johnson’s invited podium presentation is titled “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using Novel Microfluidic and Molecular Genomic Methods” and will take place during the Engineering Antibodies conference at 11:25 a.m. EDT on May 2, 2018, at the Seaport World Trade Center in Boston, Mass.

 

Read the full press release.

GigaGen CEO David Johnson to Present Data from Surge Platform at American Association for Cancer Research Annual Meeting 2018

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present data from the company’s proprietary Surge platform at the American Association for Cancer Research (AACR) Annual Meeting 2018. The conference will take place April 14-18, 2018, at the McCormick Place in Chicago.

Read the full press release.

Nature Biotechnology: GigaGen Recognized as One of the Top Biotech Startups Funded in 2017

,

Our annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine.

Read the full story.

GigaGen Presents Methods for Rapid Immuno-Oncology Antibody Discovery at 2018 Keystone Symposia on Antibodies as Drugs

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, presented preclinical research on its industry-leading Surge™ technology at the 2018 Keystone Symposia on Antibodies as Drugs: Translating Molecules into Treatments. In its research, GigaGen used Surge, a high-throughput single cell droplet microfluidic technology, to rapidly discover high-affinity, fully human antibody drug candidates against 17 immuno-oncology targets — far exceeding what is possible through conventional hybridoma screening.

Read the full press release.

GigaGen Announces Appointment of Jan Fredrik Simons, Ph.D., as Senior Director, Technology

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Jan Fredrik Simons, Ph.D., has joined the company as Senior Director, Technology.

Read the full press release.

Biotech Showcase 2018

,

David S. Johnson, PhD, MBA, Chief Executive Officer and Co-Founder, GigaGen, speaks to SCRIP about the company’s pipeline and business strategy.

Watch the video.

GigaGen to Present Novel Antibody Development and T Cell Discovery Methods at 2018 Keystone Symposia Conferences

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, will be presenting the findings of its research on novel approaches to antibody development and T cell discovery for diseases of immune dysregulation at two upcoming Keystone Symposia conferences. The first conference, “Emerging Cellular Therapies: T Cells and Beyond,” will take place Feb. 11-15 in Keystone, Colo., and the second, “Antibodies as Drugs: Translating Molecules into Treatments,” will be held Feb. 25-March 1 in Whistler, British Columbia.

Read the full press release.

Life Science Leader: GigaGen CEO Dave Johnson discusses what Drug Developers can learn from Silicon Valley

,

I think Silicon Valley’s most valuable asset is a ruthless focus on experimenting with product- market fit. Silicon Valley software companies have the mentality of pushing out products, getting market feedback, and then going back to the drawing board if the market responds poorly. Imperfect products are a learning experience — an experiment — rather than a reason to close shop or fire people.

Read the full story.